Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
Sponsor: Alexion Pharmaceuticals, Inc.
Summary
This is a noninterventional cohort study using primary and secondary data from the International PNH Interest Group (IPIG) PNH registry. It is designed to characterize the long-term safety and tolerability of danicopan as add-on therapy to eculizumab or ravulizumab in adult participants with PNH.
Official title: An Observational Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-08-18
Completion Date
2029-07-01
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
Danicopan
Participants will receive Danicopan as an add-on therapy.
Locations (1)
Alexion Pharmaceuticals, Inc. (Sponsor)
Boston, Massachusetts, United States